Employees: 1001-5000
Founded date: 1926
Mentions in press and media 12
| Date | Title | Description |
| 11.01.2026 | STRM.BIO Secures $8M Seed 2, Propelling Non-Viral Gene Therapy Revolution | STRM.BIO, a Cambridge biotech, closed an $8M Series Seed 2 round. It drives non-viral gene therapy innovation. Its MV platform delivers genetic medicines for in vivo cell engineering. Total recent funding hit $16.4M. Funds advance the pipel... |
| 08.01.2026 | STRM.BIO: $8 Million Series Seed 2 Closed To Advance Non-Viral Gene Delivery For In Vivo Cell Engineering And Gene Therapy | STRM.BIO raised $8 million in a Series Seed 2 financing to advance its non-viral gene delivery platform for in vivo cell engineering and gene therapy. The round included funding from Recordati, with continued participation from Boehringer I... |
| 07.01.2026 | STRM.BIO Raises $8M in Series Seed 2 Financing | STRM.BIO, a Cambridge, MA-based biotechnology company advancing non-viral delivery technologies for in vivo cell and gene therapy, raised $8M in Series Seed 2 financing. The round was led by Recordati with participation form Boehringer Inge... |
| 07.07.2025 | Nuevocor Strengthens Board with Appointment of Thierry Abribat | SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board o... |
| 02.05.2025 | The New Wave of Acquisitions: Navigating Tariff Turbulence and Gaming Growth | In the ever-shifting landscape of global business, two companies stand out: Recordati and Dream Games. Both are poised for growth, but their paths diverge. Recordati, an Italian pharmaceutical firm, eyes acquisitions amid tariff volatility.... |
| 30.04.2025 | Italy’s Recordati Sees Tariff Volatility Fueling Dealmaking | (Bloomberg) -- Italian drugmaker Recordati SpA is on the lookout for acquisitions, saying market volatility and the impact of tariffs have created the potential for cheaper buyouts. Recordati, which is backed by private equity firm CVC Capi... |
| 19.07.2024 | BioGaia signs a distribution agreement with Recordati in Italy | BioGaia signs a distribution agreement with Recordati in Italy Fri, Jul 19, 2024 15:40 CET Report this content BioGaia has entered into an exclusive distribution agreement with Recordati in Italy for BioGaia’s probiotic products. BioGaia si... |
| 08.07.2024 | Ligand to Acquire Apeiron Biologics, for $100M | Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a San Diego, CA-based biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines, acquired Apeiron Biologics AG, a Vienna, Austria-b... |
| 05.03.2024 | Carglumic Acid Market Size Worth $281.81 Million by 2033: The Brainy Insights | - |
| 28.10.2021 | RECORDATI: 2021 FIRST NINE MONTHS RESULTS APPROVED. REVENUE +5.7%, EBITDA +2.1% AND NET INCOME +8.1%. THE RECOVERY BEGUN IN THE SECOND QUARTER CONTINUES | NEWS RELEASE RECORDATI: 2021 FIRST NINE MONTHS RESULTS APPROVED REVENUE +5.7%, EBITDA +2.1% AND NET INCOME +8.1% THE RECOVERY BEGUN IN THE SECOND QUARTER CONTINUES Consolidated net revenue € 1,156.2 million, +5.7% (+8.6% at constant exchang... |
Show more